These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Bioreducible polymers for efficient gene and siRNA delivery. Jere D; Arote R; Jiang HL; Kim YK; Cho MH; Cho CS Biomed Mater; 2009 Apr; 4(2):025020. PubMed ID: 19349651 [TBL] [Abstract][Full Text] [Related]
43. Delivery of nanoparticulate drug delivery systems via the intravenous route for cancer gene therapy. Hallaj-Nezhadi S; Lotfipour F; Dass CR Pharmazie; 2010 Dec; 65(12):855-9. PubMed ID: 21284252 [TBL] [Abstract][Full Text] [Related]
44. Nanomedicinal delivery approaches for therapeutic siRNA. Keller M Int J Pharm; 2009 Sep; 379(2):210-1. PubMed ID: 19716034 [TBL] [Abstract][Full Text] [Related]
45. Nonviral siRNA delivery for gene silencing in neurodegenerative diseases. Prakash S; Malhotra M; Rengaswamy V Methods Mol Biol; 2010; 623():211-29. PubMed ID: 20217554 [TBL] [Abstract][Full Text] [Related]
47. Predicting the efficacy of short oligonucleotides in antisense and RNAi experiments with boosted genetic programming. Saetrom P Bioinformatics; 2004 Nov; 20(17):3055-63. PubMed ID: 15201190 [TBL] [Abstract][Full Text] [Related]
48. Supramolecular assemblies in functional siRNA delivery: where do we stand? Aliabadi HM; Landry B; Sun C; Tang T; Uludağ H Biomaterials; 2012 Mar; 33(8):2546-69. PubMed ID: 22209641 [TBL] [Abstract][Full Text] [Related]
49. Application of antisense oligonucleotides for gene functionalization and target validation. Bennett CF; Cowsert LM Curr Opin Mol Ther; 1999 Jun; 1(3):359-71. PubMed ID: 11713801 [TBL] [Abstract][Full Text] [Related]
50. Molecular therapy in support to radiotherapy. Dutreix M; Cosset JM; Sun JS Mutat Res; 2010; 704(1-3):182-9. PubMed ID: 20067843 [TBL] [Abstract][Full Text] [Related]
51. siRNA therapeutics in the treatment of diseases. Bakhtiyari S; Haghani K; Basati G; Karimfar MH Ther Deliv; 2013 Jan; 4(1):45-57. PubMed ID: 23323780 [TBL] [Abstract][Full Text] [Related]
52. Challenges for RNAi in vivo. Paroo Z; Corey DR Trends Biotechnol; 2004 Aug; 22(8):390-4. PubMed ID: 15283982 [TBL] [Abstract][Full Text] [Related]
53. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mook OR; Baas F; de Wissel MB; Fluiter K Mol Cancer Ther; 2007 Mar; 6(3):833-43. PubMed ID: 17363479 [TBL] [Abstract][Full Text] [Related]
54. Strategies for tumor-directed delivery of siRNA. Chowdhury EH Expert Opin Drug Deliv; 2011 Mar; 8(3):389-401. PubMed ID: 21314230 [TBL] [Abstract][Full Text] [Related]
55. DNA and carbon nanotubes as medicine. Cheung W; Pontoriero F; Taratula O; Chen AM; He H Adv Drug Deliv Rev; 2010 Apr; 62(6):633-49. PubMed ID: 20338203 [TBL] [Abstract][Full Text] [Related]
56. The zebrafish as a novel system for functional genomics and therapeutic development applications. Nasevicius A; Ekker SC Curr Opin Mol Ther; 2001 Jun; 3(3):224-8. PubMed ID: 11497344 [TBL] [Abstract][Full Text] [Related]
58. siRNA therapy for cancer and non-lethal diseases such as arthritis and osteoporosis. Shi Q; Zhang XL; Dai KR; Benderdour M; Fernandes JC Expert Opin Biol Ther; 2011 Jan; 11(1):5-16. PubMed ID: 21058934 [TBL] [Abstract][Full Text] [Related]
59. Local co-administration of gene-silencing RNA and drugs in cancer therapy: State-of-the art and therapeutic potential. Larsson M; Huang WT; Liu DM; Losic D Cancer Treat Rev; 2017 Apr; 55():128-135. PubMed ID: 28363142 [TBL] [Abstract][Full Text] [Related]